Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 18, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") today announced that all proposals put forth at the Special Meeting of Stockholders of CDT, held on Tuesday, March 17, 2026, were duly passed by the stockholders. "Following the successful passing of all the proposals at yesterday's Special Meeting, CDT Equity continues to transform through its $123M investment in Sarborg, the continued expansion of its IP portfolio, potential access to significant new capital and a carefully controlled annual overhead of less than $8 million," said Dr. Andrew Regan, Chief Executive Officer. "Utilizing cutting edge AI and an
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 12, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today notes the announcement from Sarborg Limited regarding the expansion of its proprietary AI Signature Agent platform through the curation of a rare disease signature database. Sarborg announced that it has curated a database containing approximately 1,700 rare disease signatures, building upon its existing disease signature library of more than 1,600 conditions, as well as its agrochemical and bacterial signature datasets previously announced. According to Sarborg, structuring rare diseases as machine-interpretable biological signatures enables rapid an
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 05, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") today notes the announcement issued by Sarborg Limited ("Sarborg") regarding the filing of a U.S. provisional patent application relating to its proprietary AI Signature Agent. CDT holds a 20% equity stake in Sarborg and views this filing as an important step in strengthening and formalising Sarborg's intellectual property position. Sarborg announced that a provisional patent application was filed with the United States Patent and Trademark Office on February 12, 2026, and has been assigned United States Patent Application No. 63/981,801. The application re
4 - CDT Equity Inc. (0001896212) (Issuer)
4 - CDT Equity Inc. (0001896212) (Issuer)
4 - CDT Equity Inc. (0001896212) (Issuer)
SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)
SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)
SC 13G - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)
Conduit Pharmaceuticals strengthens its Board of Directors with the addition of Simon Fry, a seasoned investment banking executive with over 30 years of experience in asset management, capital markets, and strategy development. NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company"), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development, today announces the appointment of Simon Fry to its Board of Directors. Mr. Fry has over 30 years' experience in investment banking having held senior executive positions at various top-tier in
SAN DIEGO and LONDON, June 13, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) (the "Company" or "Conduit"), today announced the Company is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on Friday, May 24th, 2024. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automat
Conduit also appoints prominent intellectual property attorney Jeffrey Lindeman as a Consultant Leadership additions underscore Conduit's commitment to strengthening and broadening its intellectual property portfolio through solid-form technology to maximize future value SAN DIEGO and LONDON, March 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit Pharmaceuticals" or "Conduit" or the "Company") today announced the appointment of Dr. Joanne Holland as Chief Scientific Officer. Dr. Holland brings over 20 years of experience to the CSO role at Conduit, having amassed expertise across the entire development spectrum. This includes a deep knowledge base in ide
8-K - CDT Equity Inc. (0001896212) (Filer)
8-K - CDT Equity Inc. (0001896212) (Filer)
DEF 14A - CDT Equity Inc. (0001896212) (Filer)
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced that it has entered into a strategic transaction to acquire a 20% equity stake in Sarborg Limited ("Sarborg"), an agentic AI signature intelligence business operating across multiple industrial sectors. The investment formalizes and deepens the existing collaboration between CDT and Sarborg, which has already supported the evaluation of CDT's clinical assets through Sarborg's proprietary signature analysis and artificial intelligence capabilities. Sarborg's business is built on the principle that biological, chemical and industrial signatures
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Oct. 17, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced the acquisition of 9.25648743 Bitcoin ("BTC") for an aggregate purchase price of $1,005,000 (gross of fees), at an average acquisition price of $108,301.75 per BTC. Following this transaction, CDT's total Bitcoin holdings now stand at 17.9090111 BTC. This acquisition marks a continued execution of CDT's cryptocurrency treasury reserve strategy, aimed at diversifying the Company's balance sheet and enhancing long-term shareholder value through the prudent accumulation of digital assets. "CDT remains committed to strategically deploying capita
Includes Conduit's first composition of matter patent filing for AZD5658 and multiple new combination filings for AZD1656 and AZD5658Patents derived from AI-led analysis conducted in partnership with Sarborg Limited NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (NASDAQ:CDT) ("Conduit" or the "Company") today announces the filing of four new patent applications relating to its key assets AZD1656 and AZD5658, including the Company's first patent filings for AZD5658. These filings represent a significant expansion of Conduit's intellectual property portfolio, further supporting its strategy to advance and license differentiated, IP